Aurobindo Pharma reported INR71.91B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Cipla INR 10.18B 2.22B Mar/2026
Divis Laboratories Ltd INR 1.28B 2.87B Mar/2026
Dr.Reddys Laboratories INR 11.2B 4.16B Jun/2026
Hindustan Unilever INR 25.83B 18.59B Mar/2026
Sun Pharmaceuticals INR 97.71B 15.61B Mar/2026
UPL INR 59.75B 18.23B Mar/2026